Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study.
Duffaud F, van der Burg ME, Namer M, Vergote I, Willemse PHB, ten Bokkel Huinink W, Guastalla JP, Nooij, Kerbrat P, Piccart M, Tumolo S, Favalli G, van der Vange N, Lacave AJ, Wils J, Splinter TA, Einhorn N, Roozendaal KJ, Rosso R, Vermorken JB. Duffaud F, et al. Among authors: van der vange n. Anticancer Drugs. 2001 Feb;12(2):159-62. doi: 10.1097/00001813-200102000-00010. Anticancer Drugs. 2001. PMID: 11261890 Clinical Trial.
Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
van der Vange N, van Goethem AR, Zoetmulder FA, Kaag MM, van de Vaart PJ, ten Bokkel Huinink WW, Beijnen JH. van der Vange N, et al. Eur J Surg Oncol. 2000 Nov;26(7):663-8. doi: 10.1053/ejso.2000.0978. Eur J Surg Oncol. 2000. PMID: 11078613 Clinical Trial.
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. Among authors: van der vange n. J Clin Oncol. 1999 Mar;17(3):747-55. doi: 10.1200/JCO.1999.17.3.747. J Clin Oncol. 1999. PMID: 10071262 Clinical Trial.
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, Beijnen JH, Bartelink H, Begg AC. van de Vaart PJ, et al. Among authors: van goethem ar, van der vange n, van tellingen o. Eur J Cancer. 1998 Jan;34(1):148-54. doi: 10.1016/s0959-8049(97)00370-5. Eur J Cancer. 1998. PMID: 9624250 Clinical Trial.
Breast cancer and pregnancy.
van der Vange N, van Dongen JA. van der Vange N, et al. Among authors: van dongen ja. Eur J Surg Oncol. 1991 Feb;17(1):1-8. Eur J Surg Oncol. 1991. PMID: 1995352 Review. No abstract available.
Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix.
de Gruijl TD, Bontkes HJ, van den Muysenberg AJ, van Oostveen JW, Stukart MJ, Verheijen RH, van der Vange N, Snijders PJ, Meijer CJ, Walboomers JM, Scheper RJ. de Gruijl TD, et al. Among authors: van der vange n, van den muysenberg aj, van oostveen jw. Eur J Cancer. 1999 Mar;35(3):490-7. doi: 10.1016/s0959-8049(98)00371-2. Eur J Cancer. 1999. PMID: 10448305
27 results